Online Inquiry

Global Services. (Creative Biolabs Authorized)

In Vivo CAR Bioanalysis & Testing Services

Online Inquiry

Background Service What We Can Offer Workflow Specialty Services Highlights FAQs Contact

Creative Biolabs delivers advanced In Vivo CAR Bioanalysis & Testing Services to enable in-depth assessment of CAR cell dynamics, tissue trafficking, safety characteristics, and therapeutic translation. By overcoming challenges such as complex pharmacokinetic behaviors, assay inconsistency, limited target cell abundance, and heterogeneous biodistribution, our services provide reliable insights to accelerate CAR therapy development. Through advanced quantitative PCR (qPCR), droplet digital PCR (ddPCR), multiparameter flow cytometry, and multiplex biomarker analysis platforms, Creative Biolabs enables precise monitoring of CAR persistence, cellular dynamics, and biological responses to support regulatory submissions and next-generation CAR therapeutic development.

Introduction

Cellular immunotherapies are classified as "living drugs" due to their unique capacity for in vivo proliferation, persistence, and multiphasic kinetics (distribution, expansion, contraction, and long-term persistence). Published literature demonstrates that traditional small-molecule pharmacokinetic models fail to evaluate these living therapeutics, necessitating validated cellular kinetics (CK) and biodistribution frameworks. Standardizing dual-modality testing, combining molecular assays for target sensitivity with flow cytometry for phenotypic viability, is vital for fulfilling regulatory requirements and driving success in human trials.

Fig.1 Methodologies for chimeric antigen receptor (CAR) measurement. (AI-generated) Fig.1 Assay techniques targeting chimericantigen receptor (CAR).

Service

Evaluating the in vivo behavior of engineered CAR therapies requires specialized bioanalytical strategies that capture dynamic biological responses. Creative Biolabs delivers end-to-end analytical solutions tailored for CAR-T, CAR-NK, and CAR-M programs across preclinical and clinical trial phases. Our services resolve critical hurdles in quantifying cellular kinetics, assessing tissue-specific trafficking, and evaluating host immune reactions.

By partnering with Creative Biolabs, clients receive:

Precise Transgene Quantification: Absolute copy-number determination in blood, bone marrow, and solid organs to establish clear profiles of expansion and persistence.
Comprehensive Phenotypic Profiling: Simultaneous tracking of CAR cell viability, CD4/CD8 ratios, differentiation stages, and functional exhaustion markers.
Organ Biodistribution Mapping: Clear profiles of target tumor infiltration and potential off-target tissue accumulation.
Integrated Safety Insights: Multiplexed systemic cytokine measurements to assess risks such as cytokine release events and immunogenicity profiles.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Evaluation of CAR Bioanalysis & Testing Services. (Creative Biolabs Original)

Creative Biolabs offers four core bioanalytical technologies for in vivo CAR evaluation: qPCR for high-throughput transgene persistence tracking; ddPCR for ultra-sensitive, inhibitor-tolerant absolute quantification and biodistribution mapping; multiparameter flow cytometry to evaluate viable CAR cells, memory subsets, and exhaustion markers; and multiplex immunoassay profiling to monitor cytokine release and immunogenicity.

Our Workflow

Required Starting Materials:

Biological specimens (e.g., cryopreserved whole blood, isolated PBMCs, fresh or frozen tissue biopsies from tumor/organs, or purified genomic DNA).
Specific CAR construct details (scFv sequence, vector backbone promoter elements, or target surface antigen specifications).
Study parameters including animal model specifics, dosing schedules, and preferred sampling timepoints.

Workflow of CAR Bioanalysis & Testing Services. (Creative Biolabs Original)

Specialty Services

CAR Vector Pharmacokinetics (PK) & In Vivo Shedding Detection Services

Comprehensive characterization of CAR vector biodistribution, persistence, clearance, and shedding kinetics using advanced molecular detection platforms to evaluate in vivo exposure profiles, tissue distribution patterns, safety risks, and regulatory requirements for CAR therapy development.

Learn More →

Humoral & Cellular Anti-CAR Immunogenicity Evaluation Services

Systematic assessment of humoral and cellular immune responses against CAR constructs through anti-CAR antibody detection, immune cell activation analysis, and cytokine profiling to identify immunogenicity risks and evaluate potential impacts on CAR persistence, safety, and therapeutic efficacy.

Learn More →

CAR-Mediated Pharmacodynamics (PD) & Immune Phenotypical Biomarker Analysis

Integrated analysis of CAR-mediated pharmacodynamic responses and immune phenotypic biomarkers, including CAR activity, immune cell activation, differentiation status, and functional changes to characterize therapeutic mechanisms and treatment responses.

Learn More →

CAR Therapy Clinical Safety Endpoint Monitoring Services

Integrated monitoring of clinical safety endpoints for CAR therapies, including cytokine release profiles, immune activation markers, toxicity indicators, and treatment-related adverse events to support comprehensive safety evaluation, risk management, and clinical translation.

Learn More →

Ultra-Sensitive Minimal Residual Disease (MRD) Evaluation Services for CAR Therapy

Advanced minimal residual disease detection and quantification using ultra-sensitive molecular and cellular analysis technologies to monitor residual tumor burden, assess therapeutic response, evaluate relapse risk, and support clinical efficacy analysis of CAR therapy programs.

Learn More →

Core Benefits

Dual-Modality Technical Excellence: Seamless integration of ultra-sensitive molecular assays (qPCR and ddPCR) with high-dimensional multiparameter flow cytometry for complete cellular kinetics profiling.
Versatile Matrix & Tissue Capabilities: Validated protocols for extracting high-purity gDNA and isolating viable cells across challenging biological matrices, including whole blood, bone marrow aspirates, spleen, and solid tumor tissues.
Ultra-Sensitive & Inhibitor-Tolerant Profiling: Advanced ddPCR capabilities offering absolute target copy quantification without standard curves, delivering high tolerance against complex tissue PCR inhibitors.

FAQs

Q: Why should we use both ddPCR and flow cytometry for in vivo CAR tracking?

A: The ddPCR offers ultra-sensitive absolute quantification of vector DNA, ideal for low cell counts, long-term persistence tracking, and solid tissue extracts where intact cell recovery is difficult. Flow cytometry complements this by directly measuring viable, surface-expressing CAR cells and assessing functional states such as memory subset conversion and exhaustion.

Q: Can you detect CAR transgene levels in challenging solid tissue matrices?

A: Yes. We have established tissue homogenization and extraction protocols for difficult matrices, including bone marrow, spleen, liver, lung, brain, and solid tumor tissues. Using optimized ddPCR assays, we achieve high signal-to-noise ratios even in the presence of tissue-derived PCR inhibitors.

Partner with Us

Creative Biolabs offers an integrated bioanalytical platform designed to resolve the complexities of "living drug" testing. From high-sensitivity molecular copy number determination and multi-parameter flow cytometry to cytokine release evaluation and biodistribution mapping, our team delivers the quality data required to advance your CAR-T, CAR-NK, or CAR-M candidates with confidence. Ready to accelerate your cell therapy development pipeline? Contact our bioanalysis team directly to discuss your study parameters, request a technical quote, or schedule a scientific consultation.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.